Summarize and humanize this content to 2000 words in 6 paragraphs in English We recently published a list of Starter Stock Portfolio 12 Safe Stocks to Buy. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best beginner stocks. The US stock market has experienced a turbulent first quarter of 2025, marked by increased volatility and negative returns across the major indices. Concerns surrounding tariffs, economic data, and the performance of key technology stocks contributed to this challenging period for investors. The year began with the revelation of DeepSeek, an Artificial Intelligence (AI) software developed in China, which rivalled its US competitors, such as ChatGPT. The software was considered revolutionary compared to others, sending shockwaves across the global markets. Reuters reported a global investor sell-off across US indexes, with one of the major tech companies alone losing $593 million in one day. The US government was quick to implement policies that are aimed to promote US-listed tech firms while simultaneously reducing the impact of the DeepSeek AI, such as the use of tariffs against trade with Chinese firms. The uncertainty of the US economy added to the market volatility after the Federal Reserve announced it would maintain interest between 4.25% and 4.50% in the short term. The banking sector, which is considered a good investment during times of high interest rates, is not completely immune. Analysts who previously considered 2025 to be a low-interest rate year will now price in the impact of possible NPLs (non-performing loans) due to consistent fed rates. In March, President Trump announced further global tariffs on Europe and China, fuelling the concerns of investors. In retaliation, Europe introduced counter tariffs. Emily Bowersock Hill, CEO and founding partner at Bowersock Capital Partners, which has $850M in assets under management, responded in an email to the methodology in calculating the tariffs by the US as: “So simplistic, and frankly primitive as to leave the market wondering, did its architects ever take Econ 101?” The US announced tariffs of 54% on Chinese goods, which will take effect on April 9, 2025. China, in response, implemented “reciprocal” tariffs on US goods of 34%, as reported by the country’s official Xinhua News Agency. This led to the US market indexes experiencing the biggest drop since COVID-19, with investors concerned about the impact of these tariffs on the supply chains of companies globally. The US economy is considered to be entering “continuous stagflation”, which is defined as continued inflation with very low growth and high unemployment. The Cboe Volatility Index (aka VIX) is currently at 29.68%, well above its 1-year average of 17.6%. In such economic conditions, investors should seek stocks which should provide steady/ growing revenue, dividend growth, low cyclicality, and significant cash flows and have a durable competitive advantage. Systemically important sectors are thus ideal for investors, including energy, real estate, healthcare, finance, and tech. For this list, we analyzed the Tech, Finance, Real Estate, Energy, and Healthcare industries to identify the top stocks for each sector and their historical performance against the market. We then used Insider Monkey’s Q4 2024 proprietary hedge fund holdings database and identified the 12 most popular hedge fund stocks. The stocks are ranked in ascending order of their hedge fund positions. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). Is Eli Lilly and Company (LLY) the Best Beginner Stock? No. of Hedge Fund Holders: 115 Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical company focused on discovering, developing, and marketing human pharmaceuticals. The company offers a wide range of treatments across several therapeutic areas, with a portfolio that includes various insulin formulations under the Humalog and Humulin brands, as well as newer medications like Jardiance, Mounjaro, Trulicity, and Zepbound for obesity and type 2 diabetes. Eli Lilly and Company (NYSE:LLY) actively collaborates with other pharmaceutical and biotechnology companies, including Incyte, Boehringer Ingelheim, Roche, and others, to advance its research and development efforts across its diverse therapeutic pipeline. The company markets its products in the United States, Europe, China, Japan, and other international markets. Eli Lilly and Company’s (NYSE:LLY) Q4 2024 earnings report revealed a topline of $13.53 billion, an EPS of $5.32, and an operating income of $5.6 billion. The pharmaceutical giant continues to deliver high-quality medicine to patients globally despite fears of supply chain constraints. Chairman & CEO David Ricks highlighted the company’s stellar 2024 performance during the most recent earnings call by stating: “2024 was a productive year for Lilly. We grew our top line, advanced our pipeline, and invested in our supply chain to meet the increasing demand for our medicines. Most importantly, we delivered for patients by bringing life-changing medicines to more people around the world. In 2024, full year revenue grew 32% compared to 2023, exceeding our first time guidance by $4 billion. Revenue grew 45% in the most recent quarter.” This shows that the company has proactively invested in its operations to improve supply chain hurdles. On top of that, Eli Lilly and Company (NYSE:LLY) has made eight acquisitions and signed three agreements over the past 27 months, as per the company’s press releases. These begin from DICE Therapeutics in June of 2023 to the most recent, Scorpion Therapeutics, in January 2025. Analysts have a consensus on Eli Lilly and Company (NYSE:LLY) twelve-month trading price of $1,010.47, which shows an upside of 35.64%. It is among the best beginner stocks to invest in. Overall, LLY ranks 8th on our list of best beginner stocks. While we acknowledge the potential of LLY, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than LLY but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Keep Reading
